Podcast


Presenter: Dr. Michael Allan James McCormack BSc(Pharm) PharmD Samantha Moe PharmD

In episode 593, Mike and James invite Samantha Moe back to talk about a newer agent for osteoporosis. So, if you want to know all the evidence for romosozumab, tune in and all will be revealed about the benefits and harms. Show notes 1) Tools for Practice Tony Romo-sozumab: Winning touchdown in osteoporosis or interception…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here



CFPCLearn Logo

Listening to the Podcast can earn you MainPro+ Credits

Join Now

Already a CFPCLearn Member? Log in



Latest Podcasts

BS Medicine Episode #612: Can fezolinetant improve vasomotor symptoms in menopause?

In episode 612, Tina and James chat with Samantha Moe about the use of a recently approved non-hormonal medication being used for vasomotor symptoms in menopause. We go over the…
Listen 0.5 credits available

BS Medicine Episode #611: Meds for Essential Tremor: Steady solution or shaky science?

In episode 611, Tina and James talk with Samantha Moe about the use of betablockers and other medications for essential tremor. There is some evidence – much of it from…
Listen 0.5 credits available

In the Clinic Episode 52: Statins in the Elderly

In this episode of In the Clinic the team discusses Ticker Endo, a 81 year old who would like a general medication review. To earn an additional 0.25 credits, please…
Listen 0.5 credits available

Presenter(s):

Dr. Michael Allan James McCormack BSc(Pharm) PharmD Samantha Moe PharmD

This content is certified for MainPro+ Credits, log in to access


Presenter(s):

  • Dr. Michael Allan
  • James McCormack BSc(Pharm) PharmD
  • Samantha Moe PharmD

Spearkers do not have any conflicts of interest to declare.